Original Research

Construction and validation of a risk scoring model for diffuse large B-cell lymphoma based on ferroptosis-related genes and its association with immune infiltration

Dan Xiong a,1,*, Mojuan Li b,1, Chong Zeng c,*

a Departments of Hematology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, Guangdong 528300, China
b Department of Obstetrics and Gynecology, The Sixth Affiliated Hospital, South China University of Technology, Foshan, Guangdong 528200, China
c Medical Research Center and Clinical Laboratory, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, Guangdong 528300, China

ARTICLE INFO
Keywords:
DLBCL
Risk scoring model
Ferroptosis
Immune infiltration

ABSTRACT

Backgrounds: The prognostic significance of ferroptosis-related genes is well known. However, survival- and ferroptosis-related genes are not currently considered in risk scoring models for diffuse large B-cell lymphoma (DLBCL).

Materials and methods: Ferroptosis regulators and markers were downloaded from the FerrDb database. The transcriptome profiling data were collected from the cancer genome atlas (TCGA). Transcriptome data and corresponding clinical information of DLBCL were downloaded from the gene expression omnibus (GEO). The validation data were downloaded using the UCSC Xena browser. ConsensusClusterPlus was used to categorize DLBCL samples according to gene expression profiles. The survival function was plotted with the Kaplan-Meier plots. The nomogram was built using multivariate logistic regression analysis and the Cox proportional hazards regression model.

Results: Based on the GSE11318 dataset of 203 samples and 267 ferroptosis-related gene expression profiles, we identified four clusters. A total of 19 survival-related genes were found associated with ferroptosis. The prognostic risk scoring model was constructed based on the regression coefficients. The obtained area under the receiver operating characteristic curve (AUC) values were 0.769, 0.801, and 0.791 for 1-, 3-, and 5-year survival, respectively. DLBCL samples with cluster 2 or cancer stage IV have shorter survival. Correlations between the immune infiltration and risk scores of the 12 immune cells were demonstrated. The response of DLBCL to doxorubicin was effectively validated by the risk scoring model.

Conclusions: In this study, a ferroptosis-based risk scoring model for patients with DLBCL was constructed and validated in an independent dataset. This risk score model has a better efficacy in predicting survival compared to clinical characteristics.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that accounts for approximately 30% of malignant lymphomas [1]. As a clinical and genetic heterogeneous lymphoid malignancy, DLBCL exhibits a wide range of clinical outcomes and molecular signatures [2]. Patients typically display rapidly expanding lymphadenopathy and constitutional symptoms that necessitate immediate treatment [3]. More than half of DLBCL patients can be cured by current multidrug chemotherapy, radiation and immunotherapy regimens combined with

Abbreviation: DLBCL, diffuse large b-cell lymphoma; TCGA, the cancer genome atlas; GEO, the gene expression omnibus; AUC, area under the receiver operating characteristic curve; LncRNA, long non-coding RNAs; miRNA, microRNA; UCSC, The University of California Santa Cruz; LASSO, least absolute shrinkage and selection operator; GO, gene ontology; BP, biological process; MF, molecular function; CC, cellular component; KEGG, Kyoto encyclopedia of genes and genomes; LDH, lactic dehydrogenase; NK, natural killer cells; ROC, the receiver operating characteristic.

* Corresponding authors.

E-mail addresses: xiongdancn@aliyun.com (D. Xiong), wonder10@126.com (C. Zeng).

1 These authors contributed equally to this work.

https://doi.org/10.1016/j.tranon.2021.101314
Received 22 September 2021; Received in revised form 22 November 2021; Accepted 8 December 2021
1936-5233/© 2021 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
autologous stem cell transplantation, which is one of the successes of modern cancer treatment [4,5]. Recently, several whole-genome and whole-exome sequencing studies have reported more than 200 DLBCL genes with recurrent mutation [6–9], likely located in genes functionally associated with DLBCL tumors [10,11]. Ferroptosis has been recently revealed correlated with resistance to chemotherapeutic drugs and associated with the anti-tumor efficacy of immunotherapy [12,13]. Hence, therapeutic exploitation based on ferroptosis has shown to be of interest for cancer treatment.

Ferroptosis is an iron-dependent and oxidative form of cell death, distinct from autophagy, classic necrosis, apoptosis and other forms of cell death [14]. The bluntness of cellular glutathione-dependent antioxidant defenses initiates ferroptosis process, causing the enrichment of toxic lipid reactive oxidative species, membrane damage and then cell lysis [15]. Different degrees of ferroptosis sensitivity have been observed in cancer cells from different tissues [16,17], suggesting a roles of ferroptosis in cancer development. Recently, experimental data showed that cholesterol uptake-addicted lymphoma cells decrease glutathione peroxidase expression, leading to an accumulation of membrane-oxidized lipids and cell death by a mechanism consistent with ferroptosis [18]. Studies confirmed that imidazole ketone erastin used as ferroptosis inducers, causes glutathione depletion and lipid peroxidation, exerting an antitumor effect in DLBCL [19]. In Burkitt’s lymphoma, artesunate was demonstrated to induce ferroptosis, leading to an endoplasmic reticulum stress response [20]. In addition, the prognostic significance of ferroptosis-related genes is becoming increasingly recognized [21,22]. Of particular interest, survival-related ferroptosis factors can be used for DLBCL scoring. Moreover, ferroptosis has been recently associated with resistance to chemotherapeutic drugs and associated with the anti-tumor efficacy of immunotherapy. Therefore, using ferroptosis as a therapeutic strategy is of interest for treatment of cancers, including DLBCL.

Risk score models are statistical tools used to estimate the absolute risk of a disease, for instance, DLBCL, in the future for currently healthy individuals with specific risk factors [23–25]. With risk assessment models, it is possible to predict the distribution of absolute risk in a given population and ascertain individuals at high risk, contributing to intensive surveillance and chemoprevention [25–27]. Hence, it is necessary to improve the accuracy of risk evaluation and prognosis for DLBCL. Currently, a number of risk scoring models are available for DLBCL. For example, Saez et al. built a biological predictive model using eight protein markers to assign patients with DLBCL to different risk categories [25].

Fig. 1. Consensus clustering analysis obtained 4 clusters of DLBCL based on ferroptosis-related genes expression signature. (A) The consensus clustering heatmap of 267 ferroptosis-related genes from 203 samples (GSE11318 from GEO); (B) The Kaplan-Meier survival probability of 204 patients with DLBCL categorized into 4 clusters; (C) The heatmap for the 267 ferroptosis-related gene expression and 203 DLBCL samples. DLBCL, diffuse large B-cell lymphoma.
and inflammatory genes and non-coding RNA like long non-coding RNAs (lncRNAs) and microRNA (miRNA) have also been used to establish risk scoring models [28–30]. Recently, Chen et al. established a personalized risk assessment model based on ferroptosis-related gene signature for patients with DLBCL [31]. However, whether these ferroptosis-related genes are associated with survival remains to be investigated.

Studies have shown that ferroptosis has great potential in the...
treatment of cancer, and ferroptosis inducers such as sorafenib are currently used in the clinic. Studies have shown that ferroptosis shows great potential in the treatment of cancer [32, 33]. In this study, we first obtained disease-related ferroptosis and performed clustering analysis. Then, we screened the prognosis-related ferroptosis factors and constructed a risk scoring model based on ferroptosis factors, followed by validation for its efficacy. The differences in prognosis between high and low risk were also analyzed.

**Materials and methods**

**Data collection of ferroptosis regulators and markers**

Ferroptosis regulators and markers were downloaded from the FerrDb database (URL: http://www.zhounan.org/ferrdb). In summary, 259 regulators, including 150 drivers (http://www.zhounan.org/ferrdb/fordownload/1_info_driver.csv) and 109 suppressors (http://www.zhounan.org/ferrdb/fordownload/1_info_suppressor.csv) were gathered, and 123 markers (http://www.zhounan.org/ferrdb/fordownload/1_info_marker.csv) were collected.

**Collection of transcriptome data for DLBCL**

The transcriptome profiling data were collected from the cancer genome atlas (TCGA), and the transcriptome data was saved as HiSeqV2 (https://tcga-xena-hub.s3.us-east-1.amazonaws.com/latest/TCGA.DLBC.sampleMap%2FHiSeqV2.gz), and the corresponding clinical data were stored in DLBC_survival.txt file (https://tcga-xena-hub.s3.us-east-1.amazonaws.com/latest/survival%2FDLBC_survival.txt.gz). Meanwhile, transcriptome data and corresponding clinical information of DLBCL were downloaded from the gene expression omnibus (GEO) using the University of California Santa Cruz (UCSC) Xena browser. The GEO accession NO. was GSE11318, and the clinical information was saved in clinical_GPL570.csv. When a gene has multiple expressions in the same sample, the expression of the one with the largest mean expression is retained.

**Validation data and medicine information for DLBCL**

The validation data were downloaded using the UCSC Xena browser. The transcriptome data with a GEO accession NO. GSE10846 and clinical information saved in clinical_GSE10846.csv and clinical_GSE10846_stage.txt were derived from CEO database. The treatment and medicine information for DLBCL (saved in TCGA_DLBC_drug_clinical.txt) was downloaded using the TCGAbiolinks package [34].

**Bioinformatics analysis**

**Clustering analysis**

ConsensusClusterPlus (available through the Bioconductor project: http://www.bioconductor.org/) was used to categorize DLBCL samples according to gene expression profile [35]. The samples were clustered by the pam algorithm generating consensus in unsupervised class discovery. Ultimately, samples can be differentiated into subtypes based on transcriptomic data sets, allowing for the discovery of new disease subtypes or the comparative analysis of different subtypes.

**Survival analysis**

The relationship between the clustered subtypes and survival time and outcome of DLBCL was investigated. The survival function was plotted with the Kaplan-Meier plots. Between-group differences in survival functions were assessed with a weighted log-rank test was done for comparing between-group differences in survival functions. Additionally, the association between clinical indicators of DLBCL, including stage, lactate dehydrogenase ratio, and risk score and survival outcome, was investigated, and the risk and protective factors were filtered with p < 0.05.

**Screening of differentially expressed genes**

Differentially expressed genes between the clustering samples were screened using analysis of variance, and p < 0.05 was accepted. T-test was used for comparisons between the two groups, and p < 0.05 indicated the significance.
COX-LASSO regression analysis

Univariable Cox regression analysis was carried out to screen the survival- and ferroptosis-related factors. A least absolute shrinkage and selection operator (LASSO)-type regularization method was used to penalize the factor data. The obtained model shrank the coefficients for non-informative factors toward zero, the reduced variance was acquired, and clustering performance was improved. Prognostic risk scoring models associated with ferroptosis-related factors in DLBCL were constructed based on the regression coefficients of these factors.

Immune infiltration analysis

To study the immune cell profile of each sample, the cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm was used to analyze the abundance of member cell types based on gene expression data, and the CIBERSORT R package was downloaded for local use (available: http://cibersort.stanford.edu/)[36], and the solution of the kernel function is obtained by deconvolution of the SVM algorithm as the immune cell infiltration label.

Nomogram establishment for cancer prognosis

The nomogram was built using multivariate logistic regression analysis and the Cox proportional hazards regression model. Each influencing factor in the model was assigned a score at different value intervals according to the degree of contribution of the influencing factor to the outcome, i.e., the magnitude of the regression coefficient. The individual scores were then summed and obtained the total score. A functional transformation relationship between the total and the probability of the outcome was used to calculate the predictive value of the outcome for that individual. Ultimately, the complex regression equations were transformed into a visual graph, making the results of the predictive models more readable and to facilitate disease evaluation.

Results

Clustering and gene function analysis

Based on the GSE11318 dataset of 203 samples and the expression profile of 267 ferroptosis-related genes, the consensus clustering analysis identified four clusters were obtained by the consensus clustering analysis (Fig. 1A). The Kaplan-Meier survival analysis indicated that cluster 1, cluster 2, and cluster 3 had a significantly different in survival probability. Cluster 3 samples had an improved prognosis compared to cluster 1, and cluster 1 had a better prognosis compared to cluster 2 (Fig. 1B). In addition, there was a more significant difference in gene expression was found between cluster 1 and cluster 2, with a total of 115 genes were identified showing interclass differences using ANOVA (p < 0.05) (Fig. 1C). Next, we performed a functional analysis of the 115 differentially expressed genes among the four clusters was next performed. The top 9 biological processes corresponded to 33 genes, and these processes were related to the ferroptosis procedure, including responses to oxidative stress, chemical stress, extracellular stimulus, external stimulus, nutrient levels, and starvation (Fig. 2A). The 17 ferroptosis-associated genes mainly possess molecular functions like ubiquitin-protein ligase binding, tetrapyrrole binding, ubiquitin-like...
ligase binding, and heme-binding (Fig. 2B). We observed that 8 protein-coding proteins were linked to cellular components like mitochondrial outer membrane, organelle outer membrane, and outer cell membrane (Fig. 2C). KEGG pathway enrichment analysis indicated that these differentially expressed genes mediated the autophagy process, ferroptosis, necroptosis, neurodegeneration-multiple diseases, shigellosis infection, and Kaposi sarcoma-associated herpesvirus infection, etc. (Fig. 2D). Overall, survival-related ferroptosis factors show biological roles like responses to oxidative stress.

Identification of ferroptosis and survival-related genes and construction of prognostic risk scoring model

Survival-related genes were identified based on ferroptosis-related genes with different expression profiles using one-way Cox regression analysis. Here, 19 survival-related genes were found associated with ferroptosis ($p < 0.05$) (Fig. 3A). The 19 ferroptosis factors were subjected to LASSO regression analysis for dimensionality reduction. The optimal penalty value lambda in the LASSO regression was first obtained using cross-validation (Fig. 3B). The regression coefficients of the 16 ferroptosis factors were obtained based on this value (Fig. 3C). The expression differences of the genes among cluster 1, cluster 2, cluster 3, and cluster 4 were compared by t-test. The relationship between gene expression levels and survival probability was analyzed by the Kaplan-Meier survival curves. A total of 16 genes associated with ferroptosis and survival in DLBCL (Fig. 3D). Patients with high survival probability showed abundance in UBC, CAPG, EPAS1, ACVR1B, GABARAPL1, TFAP2C, and AKR1C3. However, MT1G, IREB2, TRIB3, ATF4, ATG3, CHAC1, and ULK2 were low expressed in patients with DLBCL, which was associated with high survival probability. The prognostic risk scoring model was constructed based on the regression coefficients and calculated as follows, risk Score = $-0.006906\*DRD4-0.1427\*TFAP2C-0.03086\*AKR1C3+0.08295\*CHAC1+0.2237\*ULK2+0.1026\*CXCL2-0.2478\*GABARAPL1+0.07055\*TRIB3-0.01005\*CYBB+0.4483\*IREB2-0.02139\*EPAS1+0.1521\*MT1G+0.2654\*ATG3-0.06966\*CAPG+0.4052\*ATF4+0.03599\*UBC.

Validity assessment of prognostic model

To assess the validity of the prognostic risk score model, we used the risk score predicted by the model to classify the 203 DLBCL samples into two categories based on the median score (Fig. 4A). We also analyzed the predicted results of risk score classification for 1, 3, and 5-year survival, and the obtained area under the receiver operating characteristic curve (AUC) values were 0.769, 0.801, and 0.791, respectively (Fig. 4B). Comparing the predictive validity of clinical stages, lactate dehydrogenase ratio and risk score for 3-year survivals, the obtained AUC value was 0.765 (Fig. 4C). In contrast, the predictive validity of age, gender, and risk score on 3-year survival of patients was 0.69 (Fig. 4D). The effect of clinical characteristics and risk score on patient survival was verified using univariate and multivariate Cox regression analysis, respectively, and risk score was found to be a more important risk factor (Fig. 4E, F). The expression of 16 ferroptosis-related factors in samples from high and low risk groups (Fig. 4G), sample size distribution, and patient survival status (Fig. 4H) also demonstrated a consistent association between high risk and high mortality.
we found significantly different risk scores between cluster 1 and cluster 2 and between cluster 2 and cluster 3. Among them, cluster 2 had a higher risk score than cluster 1 and cluster 3 (Fig. 4I). The risk score of cancer stage IV was also found to be significantly higher than that of stage I (Fig. 4J). These results suggest that DLBCL samples with cluster 2 or cancer stage IV are associated with shorter survival.

**Validation of the prognostic scoring model for DLBCL and external confirmation of the nomogram**

Gene expression profiles from the GSE10846 dataset and the corresponding clinical phenotypes and survival data were used to validate the constructed risk score model. The GSE10846 expression profile was input into the model, and the risk scores were obtained. Fig. 5A shows that DLBCL patients with low risk had a high survival probability. The predictive validity of risk scores for 1, 3, and 5-year survival probability is presented in Fig. 5B, with obtained AUC values of 0.673, 0.708 and 0.716, respectively. Clinical characteristics (age, gender, stage and lactic dehydrogenase ratio) and risk score for the model were found to be better predictors of patient survival (Fig. 5C). Univariate and multivariate analysis also confirmed the significant effect of risk score on patient survival (Fig. 5D). To calculate predictive values for individual outcome events, we constructed nomograms based on the effects of risk score, age, and gender on patient survival over 1, 3, and 5 years, as well as calibration curves for the nomograms (Fig. 5E). Notably, no significant difference was observed between the observed probabilities and the predicted outcomes for 1-year, 3-year, and 5-year survivals (Fig. 5F). The obtained results presented that the prediction based on an independent dataset GSE10846 was valid, which meanwhile proved the exportability of the risk scoring model for DLBCL disease.

**Association between immune infiltration and risk score for DLBCL**

Infiltration scores were assessed using CIBERSORT based on the expression profiles of all genes in 203 samples, and then the differences in immune infiltration of 22 immune cells (B cells naive, B cells memory, plasma cells, T cells CD8, T cells CD4 naive, T cells CD4 memory resting, T cells CD4 memory activated, T cells follicular helper, T cells regulatory Tregs, T cells gamma delta, NK cells resting, NK cells activated, monocytes, macrophages M0, macrophages M1, macrophages 2, dendritic cells resting, dendritic cells activated, mast cells resting, mast cells activated, eosinophils, neutrophils) were compared by t-test (Fig. 6A). It was suggested that activated CD4 memory T cells, follicular helper T cells, resting natural killer cells, activated natural killer cells, M0 and M2 macrophages, and neutrophils showed different proportions between high-risk and low-risk DLBCL. Additionally, we found that most of the ferroptosis-related and survival-related genes were positively correlated with tumor-filtrating immune cells, such as ACVR1B, CAPG, and CXCL2. A few were bidirectional, such as AKR1C3 and CAPG (Fig. 6B). We demonstrated correlations between the immune infiltration and risk score (Fig. 6C).
scores of the 12 immune cells were demonstrated. In detail, all these 12 immune cells were associated with risk scores of DLBCL samples (Fig. 6C).

Risk score for predicting the response of chemotherapy dose

To further determine the clinical usefulness of the risk scores predicted by our model, clinical data on chemotherapy dosing for DLBCL were obtained using the TCGA biolinks tool to predict chemotherapy dosing outcomes. However, the data was not unavailable for progressive clinical disease, stable disease, and other dosing responses. Finally, we used the pRRopheticPredict R package to simulate dosing responses based on expression profiles. To simulate the actual dosing response as closely as possible, we used the drug most used in DLBCL presented by the TCGA database and the drug predicted by the pRRopheticPredict R package, i.e., doxorubicin. Then, we calculated the response of DLBCL to the drug and subsequently obtained the efficacy of the dosing response predicted by the sample risk score. The predicted AUC was found to be 0.64, indicating that our data are effective predictors of clinical drug application (Fig. 7).

Discussion

One of the pivotal challenges for killing cancer cells is effectively triggering apoptotic cell death and controlling therapy-resistant cells [37]. As an iron-catalyzed form of regulated necrosis, ferroptosis is involved in the silencing or downregulation of genes initiating or executing necrosis in cancers [38,39]. DLBCL outcome is the result of interactions between the genetic abnormalities of ferroptosis-related factors and the clinical status of the patients [31,40]. Identification of clinical risk is helpful to better design the therapeutic intervention in different DLBCL patients [41,42]. Here, we report a ferroptosis-based risk scoring model for patients with DLBCL, and its validation in an independent dataset. This risk score model has a better efficacy in predicting survival compared to clinical characteristics. Additionally, the risk score suggested the consistency with immune cell infiltration in DLBCL. Of note, this model can predict the medical response of DLBCL patients to doxorubicin.

Ferroptosis is characterized by the excessive peroxidation of polyunsaturated fatty acids containing phospholipids catalyzed by iron in cell membranes [14]. Ferroptosis is being studied as a preventive strategy in several cancers, including fibrosarcoma, melanoma, ovarian cancer [17], mesothelioma [16], gastric cancer [43] and liver cancer [44]. In terms of DLBCL, imidazole ketone erastin, artesunate, and cholesterol cause lipid peroxidation, induce ferroptosis biomarkers, and result in an endoplasmic reticulum stress response in vivo and in vitro, showing a therapeutic mechanism consistent with ferroptosis [45–47]. Recently, Zhou et al. linked the ferroptosis process to metabolites and biomolecules, annotating several regulators and markers of ferroptosis, which is meaningful to linking ferroptotic process to metabolites and biomolecules in cancers [48]. According to the ferroptotic signature of cancers, we performed the consensus clustering analysis and obtained 4 clusters with different survival probabilities. The results suggested that cluster 3 and cluster 4 showed an improved prognosis compared with cluster 1 and cluster 2. These ferroptosis-related and survival-related molecules participate in stimulus-response, membrane composition, lipid oxidation, regulation of autophagy, and mitophagy, as shown in previous studies [49,50].

Furthermore, we identified 16 ferroptosis- and survival-related genes after LASSO regression analysis. A risk scoring model was developed based on 16 genes, followed by validating the discriminatory accuracy of the model by the AUC method using an independent dataset. The discriminatory accuracy was obviously improved compared with the model that only included risk factors like the clinical stage, LDH ratio, age and gender. Beside, the metabolic prognostic model has been generated to assign patients with DLBCL into high- or low-risk clusters, which shows a superiority in aspect of a short-term [51]. Other prognostic scoring models for DLBCL have been reported based on infiltrating immune cells [52] and tumor microenvironment [53]. All these models have effectively and independently determined the prognosis of patients with DLBCL. Similarly, Chen et al. reported a risk assessment model for patients with DLBCL, and this personalized model was constructed based on ferroptosis-related gene signature [31]. They established a reliable prognostic prediction for subgroup analysis using the 8-gene associated with ferroptosis [31]. Here, our study integrated 16 ferroptosis-related gene signatures and clinical factors, which showing an improved prognostic value in classifying patients with DLBCL into high- or low-risk groups.
Malignant cells change the generation of cytokines that typically govern proliferation, and consequently participate as part of a dysregulated immune environment [54,55]. Hence, understanding the types and roles of immune cells is critical to develop strategies to target tumors and improve patient prognosis. The participation of ferroptosis in T cell immunity has been confirmed by Wang et al., [17]. They reported that immunotherapy induces the activation of CD8 T cells, which fortifies ferroptosis-specific lipid peroxidation [17]. Furthermore, the genes associated with survival and ferroptosis were correlated with immune infiltration. It has been proved that ferroptosis-related genes affect immune infiltration and invasion in ovarian cancer [56] and breast cancer [57]. However, it remains unclear whether ferroptosis shows effects on immune infiltration in DLBCL. Here, we noticed that patients with high and low risk showed differences in the proportions of activated CD4 memory T cells, follicular helper T cells, resting natural killer cells, activated natural killer cells, M0 and M2 macrophages, and neutrophils. To estimate the risk of relapse and progression in patients with DLBCL treated with doxorubicin, the efficacy of the dosing response was predicted. The predicted AUC was 0.64, suggesting an effective predictor for clinical drug application.

Conclusions

In conclusion, our study established a ferroptosis-based risk scoring model for patients with DLBCL, and this model was validated in an independent dataset. The risk scoring model showed improved efficacy in predicting survival compared to clinical characteristics. In addition, the risk score showed consistency with immune cell infiltration in DLBCL. This model implemented stratification of DLBCL patients into low- and high-risk cohorts.

CRediT authorship contribution statement

Dan Xiong: Conceptualization, Supervision, Formal analysis, Writing – original draft, Writing – review & editing. Mojuan Li: Formal analysis, Writing – original draft, Writing – review & editing. Chong Zeng: Conceptualization, Writing – review & editing.

Declaration of Competing Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Availability of data and materials

Datasets used and/or analyzed in this study can be obtained from the corresponding author upon reasonable request.

Funding

This work was supported by grants from the Medical Scientific Research Foundation of Guangdong Province (grant no. B2021195), the Science and Technology Program of Foshan (grant no. 1920001000694), the key program of Shunde Hospital(grant no. SRSP2021003), the key specialty funding department of Hematology, Shunde Hospital (No. 0520).

Acknowledgments

Not applicable.

References

[1] S. Li, K.H. Young, L.J. Medeiros, Diffuse large B-cell lymphoma, Pathology 50 (1) (2018) 74-87.
[2] Miyawaki, K., et al., A Germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of diffuse large B-cell lymphoma. 2019: p. 100147.
[3] Y. Liu, S.K. Barta, Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment, Am. J. Hematol. 94 (5) (2019) 604-616.
[4] P. Skrabek, et al., Emerging therapies for the treatment of relapsed or refractory diffuse large B-cell lymphoma, J. Hematol. Oncol. 6 (2013) 253–265.
[5] L.J. Harris, K. Patel, M. Martin, Novel therapies for relapsed or refractory diffuse large B-cell lymphoma, Int. J. Mol. Sci. 21 (22) (2020) 8553.
[6] L. Pasqualucci, et al., Analysis of the coding genome of diffuse large B-cell lymphoma, Nat. Genet. 43 (9) (2011) 830-837.
[7] G. Lenz, et al., Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proc. Natl. Acad. Sci. U. S. A. 105 (36) (2008) 13520–13525.
[8] R.D. Morin, et al., Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing, Blood 122 (7) (2013) 1256–1265.
[9] J.G. Lohr, et al., Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma, J. Clin. Exp. Hematopathol. 56 (2) (2016) 71–78.
[10] X. Xia, et al., The relationship between ferroptosis and tumors: a novel landscape for therapeutic approach, Curr. Gene Ther. 19 (2) (2019) 117–124.
[11] J.F. Friedmann Angeli, D.V. Kryrok, M. Conrad, Ferroptosis at the crossroads of cancer-affected drug resistance and immune evasion, Nat. Rev. Cancer 19 (7) (2019) 405–414.
[12] S.J. Dixon, et al., Ferroptotic an iron-dependent form of nonapoptotic cell death, Cell 149 (5) (2012) 1060-1072.
[13] W.S. Yang, et al., Regulation of ferroptotic cancer cell death by GPX4, Cell 156 (1–2) (2017) 317–331.
[14] J. Wu, et al., Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signaling, Nature 572 (7769) (2019) 402–406.
[15] W. Wang, et al., CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy, Nature 569 (7755) (2019) 270–274.
[16] J.S. Rink, et al., Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis, J. Biol. Chem. (2021) 296, https://doi.org/10.1074/jbc.RA120.014888.
[17] Y. Zhang, et al., Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model, Cell Chem. Biol. 26 (5) (2019) 623–633, e9.
[18] N. Wang, et al., Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt’s Lymphoma, Biochem. Biophys. Res. Commun. 519 (3) (2019) 533–539.
[19] Y. Liu, et al., Ferroptosis-related genes are potential prognostic molecular markers for patients with colorectal cancer, Clin. Exp. Med. 21 (3) (2021) 467–477.
[20] N. Zhao, J. Bao, FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations, Database 2020 (2020) baaz021, https://doi.org/10.1093/database/baa021 (Oxford).
[21] N. Schmitz, et al., CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP, J. Clin. Oncol. 34 (26) (2016) 3150–3156.
[22] J.S. Rink, et al., Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes, N. Engl. J. Med. 350 (18) (2004) 1828–1837.
[23] A.I. Sáez, et al., Building an outcome predictor model for diffuse large B-cell lymphoma, Am. J. Pathol. 164 (2) (2004) 613–622.
[24] K. Dembrower, et al., Comparison of a deep learning risk score and standard mammographic density score for breast cancer risk prediction, Radiology 294 (2) (2020) 265–270.
[25] Q. Zhao, C. Fan, A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs, BMC Med. Genet. 20 (1) (2019) 103.
[26] T.M. Habermann, et al., Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-crituximab era, Blood 112 (7) (2008) 2694–2702.
[27] J. Sun, et al., A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma, Sci. Rep. 6 (1) (2016) 27842.
[28] R. Sun, et al., A novel prognostic model based on four circulating miRNA in diffuse large B-cell lymphoma: implications for the roles of MDCS and Th17 cells in lymphoma progression, Mol. Oncol. 15 (1) (2021) 246–261.
[29] H. Chen, et al., Ferroptosis-related gene signature: a new method for personalized risk assessment in patients with diffuse large B-cell lymphoma, Pharmgenco. Pers. Med. 14 (2021) 609-619.
[30] H. Yu, et al., Ferroptosis, a new form of cell death, and its relationships with tumourous diseases, J. Cell. Mol. Med. 21 (4) (2017) 648–657.
[31] T. Xu, et al., Molecular mechanisms of ferroptosis and its role in cancer therapy, J. Cell. Mol. Med. 23 (8) (2019) 4960-4962.
[32] A. Colapietro, et al., TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data, Nucleic Acids Res. 44 (8) (2016) e71.
[33] M.D. Wilkerson, D.N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking, Bioinformatics 26 (12) (2010) 1572–1573.
[34] A. Newman, et al., Robust enumeration of cell subsets from tissue expression profiles, Nat. Methods 12 (5) (2015) 453-457.
[35] B.A. Carneiro, W.S. El-Deiry, Targeting apoptosis in cancer therapy, Nat. Rev. Clin. Oncol. 17 (7) (2020) 395–417.
[38] K. Shimada, et al., Cell-line selectivity improves the predictive power of pharmacogenomic analyses and helps identify NADPH as biomarker for ferroptosis sensitivity, Cell Chem. Biol. 23 (2) (2016) 225–235.

[39] S. Zhuo, et al., Clinical and biological significances of a ferroptosis-related gene signature in glioma, Front. Oncol. 10 (2572) (2020) 590861.

[40] A. Schmitt, et al., Dimethyl fumarate induces ferroptosis and impairs NF-κB/STAT3 signaling in DLBCL, Blood 138 (10) (2021) 871–884.

[41] J.S. Abramson, M.A. Shipp, Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach, Blood 106 (4) (2005) 1164–1174.

[42] A.J. Saez, et al., Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma, Leuk. Lymphoma 50 (4) (2009) 571–581.

[43] H. Zhang, et al., CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer, Mol. Cancer 19 (1) (2020) 43.

[44] X. Zhang, et al., Ferroptosis is governed by differential regulation of transcription in liver cancer, Redox Biol. 24 (2019), 101211.

[45] Y. Zhang, et al., Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model, Cell Chem. Biol. 26 (5) (2019) 623–633, e9.

[46] N. Wang, et al., Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in Burkitt’s Lymphoma, Biochim. Biophys. Res. Commun. 519 (3) (2021) 533–539.

[47] J.S. Rink, et al., Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis, J. Biol. Chem. 296 (2021), 100100.